Immune System Promises Complete Tumor Elimination •Intact immunity of cancer patients•It can be directed to target cancer cells•Immunotherapy is a highly desirable alternative to current therapies Proof-of-concept for Cancer Immunothe
Feasibility
• Conversion of Th2 to Th1
• GVT effect after allogeneic BMT
• Th1 cytokines drive naïve to develop to Th1
• Th1 cytokines selectively polarise Th1
• Breaking immunotolerance of tumor
• Th1-mediated spontaneous abortion
• Th1-mediated GVHD
• Sustained Th1 inflammatory environment
T-plus Immunotherapy
Sufficient inflammatory “danger signals” potent enough to downregulate tumor-mediated immunosuppressive cytokine production and related tolerogenic mechanisms.
T-plus contains
in vitro differentiated and expanded allogeneic Th1 immune Cells. They are activated at the time of injection with anti-CD3/anti-CD28 Monoclonal antibody conjugated with nanobeads. These Th1 cells express effector molecules of CD40L and FasL on the cell surface and produce large amounts of inflammatory cytokines.
- Increase circulating number of Th1 cells, shifting Th2 to Th1
•Subcutaneous injection of allogeneic Th1 cells
- Elicit anti-tumor specific Th1 immunity
•Cryoablation with intratumoral T-plus
- Rely on the innate and adaptive immune response to generate a sustained Th1 cytokine environment
•Intravenous booster
Clinical Protocol of T-plus Immunotherapy
Eliminating cancer in the 21st Century
Establish a creative environment, bring together physicians, surgeons and scientists, and work together as a team
